Get in Touch With Us
Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!
Antibody Discovery Services
Where in vivo meets in vitro for end-to-end drug discovery solutions
A New Era in Antibody Discovery
Modern therapeutic targets are getting more challenging and traditional, single modality platforms are no longer sufficient on their own. Twist Bioscience Solutions is the union of two of the industry’s best antibody discovery service providers who together provide our partners with the “discovery trifecta” – in vivo, in vitro and in silico antibody discovery all under one roof.
Twist Biopharma Solutions' (TBS) one of a kind discovery services offer our partners improved diversity, improved screening, ultra fast lead selection and engineering, which can mean a faster path in the race to the clinic.
Workflows and Corresponding Timelines
We offer three workflow options to our partners to ensure their needs are met within their desired timelines. Choose which workflow best fits your needs, or work with a scientist to determine a path.
Our Services
We offer a full suite of capabilities to best serve our partners’ needs. Find out more about our service offerings by clicking below.
Our Numbers Speak for Themselves
400+
Successful mAb discovery campaigns completed in industry-leading timelines
200+
Partnerships spanning all therapeutic areas
4+
mAb candidates discovered by Twist Biopharma Solutions in clinical trials
3+
Industry’s best platforms spanning three different technologies to ensure all shots on goal
Companies We've Partnered With
What Scientists Have to Say
“
Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.”
ROBERT CARNAHAN, PHD
Associate Director of the Vanderbilt
Vaccine Center
“
Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.”
JEFF GOLDBERG, CEO
Associate Director of the Vanderbilt
